VivoSeq
Other

Severe Acute Respiratory Syndrome

62

Pipeline Programs↗

2

Active Trials↗

26

Companies Involved↗

Severe Acute Respiratory Syndrome is a moderately active landscape with 62 programs across 26 companies. The most active players are BeiGene, GeneCure Biotechnologies, Alnylam Pharmaceuticals. 16 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

83/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

BeiGene logo

BeiGene

1 program

Phase 1G

GeneCure Biotechnologies

1 program

Phase 1Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 1Q

Quince Therapeutics S.p.A.

1 program

Phase 1H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 1P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical6

Ritonavir

AbbVie

Methylprednisolone

Pfizer

Ribavirin

Conrado Roberto Hoffmann Filho

Thyroxine

Washington University School of Medicine

SARS-COV-2 VACCINE

Moderna

Phase 119

Hydroxychloroquine

Alnylam Pharmaceuticals

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Mrna-1345

Moderna

Phase 213

Sargramostim

Sanofi

Sarilumab

Azienda U.S.L. 1 di Massa e Carrara

Sotrovimab

Vir Biotechnology, Inc.

Bevacizumab

Bio-Thera Solutions

Ibrutinib

Pharmacyclics LLC.

Phase 38

Levosimendan

Orion Corporation, Orion Pharma

Influenza Virus Vaccine

Sanofi

Ivermectin

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Tocilizumab

Roche

Gam-COVID-Vac

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Approved16

Remdesivir

Gilead

Ketamine

Aultman Health Foundation

Fluvoxamine

Solvay Pharmaceuticals

Icatibant

Takeda

Enoxaparin

Sanofi

Analysis

Modality Breakdown

70%

Small molecule

45 of 64 classified programs — the dominant modality here.

30%ALL OTHERSVaccine711%RNA therapy69%Monoclonal antibody58%Protein / enzyme12%

Small molecule leads; the ring shows all 64 classified programs, each share of the total. Modality classified for 100% of 70 pipeline programs.

Analysis

Trial Status

41

clinical trials

Completed24 · 59%
Unknown status10 · 24%
Withdrawn3 · 7%
Terminated2 · 5%
Recruiting1 · 2%
Active, not recruiting1 · 2%

Clinical Trials

Trial Activity

41 trials

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection
Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT05656105·60 enrolled
Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)
Active, not recruiting·OOslo University Hospital·N/A·NCT04747522·150 enrolled
Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.
Completed·TTaipei City Hospital·N/A·NCT05236309·2,000 enrolled
Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
Completed·MMassachusetts General Hospital·Phase 2·NCT04306393·200 enrolled
Oral Rinse to Reduced Expelled Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During COVID-19 Infection
Completed·RRutgers, The State University of New Jersey·Phase 1·NCT04931004·34 enrolled
Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)
Completed·LLemonex·Phase 1·NCT06032000·20 enrolled
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
Completed·BeiGene logoBeiGene·Phase 1·NCT04532294·18 enrolled
Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
Completed·UUniversity of Trieste·N/A·NCT04323592·173 enrolled
Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults
Completed·IIhsan GURSEL, PhD, Prof.·Phase 1·NCT04818281·38 enrolled
Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)
Completed·SStanford University·Phase 1·NCT04567810·48 enrolled
Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2
Completed·FFundação de Medicina Tropical Dr. Heitor Vieira Dourado·Phase 2·NCT04323527·278 enrolled
Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.
Completed·LLaboratorios Silanes S.A. de C.V.·Phase 2·NCT04625985·20 enrolled
Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva
Completed·QQueen Mary University of London·N/A·NCT04723446·54 enrolled
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
Completed·Moderna logoModerna·Phase 2·NCT06508320·932 enrolled
Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine
Completed·IIhsan GURSEL, PhD, Prof.·Phase 2·NCT04962893·349 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)